LOPRESSOR INJECTION Rx
Generic Name and Formulations:
Metoprolol tartrate 5mg; soln for IV inj.
Novartis Pharmaceuticals Corp
Indications for LOPRESSOR INJECTION:
In stabilized patients after MI, to reduce mortality.
See literature. Early treatment: initially administer three 5mg IV bolus inj given at approximately 2-minute intervals; monitor BP, HR, ECG. If full IV dose (15mg) tolerable, give 50mg (tab) every 6 hours starting 15 mins after the last IV dose and continue for 48 hours, thereafter, give maintenance dose of 100mg (tab) twice daily; if full IV dose not tolerable, give 25–50mg (tab) every 6 hours starting 15 mins after the last IV dose or as soon as clinical condition allows; if severe intolerance: discontinue treatment. Late treatment: if early phase treatment is contraindicated, intolerable or delayed therapy needed, start with 100mg (tab) twice daily for at least three months.
Significant 1st degree heart block. 2nd- or 3rd-degree AV block. Systolic pressure<100mmHg or heart rate <45 beats/min. Moderate-to-severe cardiac failure.
Avoid abrupt discontinuation in ischemic heart disease.
CHF. Monitor heart rate and rhythm; reduce or stop treatment if severe bradycardia develops. Bronchospastic disease. Hepatic dysfunction. Diabetes. Pheochromocytoma. Hyperthyroidism. Surgery. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Bradycardia with catecholamine-depleting drugs. May be potentiated by potent CYP2D6 inhibitors (eg, fluoxetine, paroxetine, bupropion, thioridazine, quinidine, propafenone, ritonavir, diphenhydramine, hydroxychloroquine, terbinafine, cimetidine), hydralazine, inhalation anesthetics. Increased risk of bradycardia with concomitant digitalis. May block epinephrine. Increased rebound hypertension with clonidine withdrawal. May enhance vasoconstrictive action of ergots. Withhold before dipyridamole testing.
Fatigue, dizziness, depression, hypotension (discontinue if occurs), diarrhea, rash, dyspnea, bradycardia, cold extremities, palpitations, CHF, peripheral edema, bronchospasm, heart block.
Tabs—100; Ampuls (5mL)—10
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage